In 2018, Dr. Lena Park, Dr. Michael Torres, and Dr. Raj Patel left their positions at the Salk Institute with a shared frustration: genomic sequencing was too slow, too expensive, and too error-prone for the precision medicine revolution it was supposed to enable.
They founded Apex Biotech in a 900-square-foot wet lab in La Jolla. Within two years, their microfluidic sequencing platform had attracted $42M in Series A funding and partnerships with three top-20 pharmaceutical companies. Today, Apex operates two research campuses and has processed over 3.2 million genomes.
